ATE332135T1 - Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren - Google Patents

Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren

Info

Publication number
ATE332135T1
ATE332135T1 AT00953647T AT00953647T ATE332135T1 AT E332135 T1 ATE332135 T1 AT E332135T1 AT 00953647 T AT00953647 T AT 00953647T AT 00953647 T AT00953647 T AT 00953647T AT E332135 T1 ATE332135 T1 AT E332135T1
Authority
AT
Austria
Prior art keywords
astrocytoma
melanoma
related tumors
drugs
treatment
Prior art date
Application number
AT00953647T
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/001760 external-priority patent/WO2000044381A1/en
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Application granted granted Critical
Publication of ATE332135T1 publication Critical patent/ATE332135T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00953647T 2000-01-24 2000-07-18 Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren ATE332135T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/001760 WO2000044381A1 (en) 1999-01-28 2000-01-24 Treatment of lymphomas, leukemias, and leiomyomas

Publications (1)

Publication Number Publication Date
ATE332135T1 true ATE332135T1 (de) 2006-07-15

Family

ID=21740994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953647T ATE332135T1 (de) 2000-01-24 2000-07-18 Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren

Country Status (6)

Country Link
EP (1) EP1242084B1 (de)
AT (1) ATE332135T1 (de)
AU (1) AU784523B2 (de)
CA (1) CA2388840C (de)
DE (1) DE60029246D1 (de)
WO (1) WO2001052850A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020081334A (ko) * 2000-02-21 2002-10-26 시마르 인코포레이티드 간질 치료를 위한 조성물과 방법
ATE533486T1 (de) * 2006-06-15 2011-12-15 Shanghai Genomics Inc Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
WO1996027374A1 (en) * 1995-03-03 1996-09-12 Margolin Solomon B Treatment of cytokine growth factor caused disorders
US6114353A (en) * 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α

Also Published As

Publication number Publication date
EP1242084B1 (de) 2006-07-05
EP1242084A4 (de) 2004-01-14
WO2001052850A1 (en) 2001-07-26
EP1242084A1 (de) 2002-09-25
DE60029246D1 (de) 2006-08-17
CA2388840C (en) 2011-09-13
AU6606100A (en) 2001-07-31
AU784523B2 (en) 2006-04-27
CA2388840A1 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
MY131911A (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2h-benzopyran or dihydrobenzodioxin) carboxamide derivatives
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
MY138966A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
WO2003005999A8 (en) Methods of treating cytokine mediated diseases
MY139102A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
MX2022013051A (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos.
DK1044197T3 (da) Piperidinylsubstituerede pyridylalkan-, -alken- og -alkyncarboxamider som cytostatiske midler og immunosuppressive midler
YU21401A (sh) Tetrahidropiridoetri
DK1414813T3 (da) Antimalariamidler baseret på 1,3,4-trioxolan
NO20001483L (no) Nye NPY-agonister
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
IS6319A (is) Indólýl-3-glýoxý sýru afleiður sem innihalda gagnlega meðferðarlega eiginleika
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
CY1106713T1 (el) Συνδυασμενη θεραπεια εναντιον καρκινωματων η οποια περιλαμβανει παραγωγα υποκαταστημενης ακρυλοϋλ δισταμυσινης και αλκυλιωτικους παραγοντες
ATE479657T1 (de) N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen
IL152097A0 (en) Use of pyrazole derivatives for treating infertility

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties